This Article Full Text Full Text (PDF) Publisher's Note Erratum (v26,p2238) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Google Scholar Articles by Yu, J. B. Articles by Wilson, L. D. PubMed Articles by Yu, J. B. Articles by Wilson, L. D.

Analysis of Primary CD30+ Cutaneous Lymphoproliferative Disease and Survival From the Surveillance, Epidemiology, and End Results Database

James B. Yu, Rachel C. Blitzblau, Roy H. Decker, Douglas M. Housman, Lynn D. Wilson

From the Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT; and the Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Corresponding author: Lynn D. Wilson, MD, MPH, Department of Therapeutic Radiology, Yale University School of Medicine, HRT 132, 333 Cedar St, New Haven, CT 06520; e-mail: lynn.wilson{at}yale.edu

Purpose: Primary CD30+ cutaneous lymphoproliferative disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas. The primary intention of the analysis of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database was to report epidemiologic information and overall survival of patients with PCLPD.

Methods: We investigated the SEER database from 1973 to 2004 and performed univariable and multivariable survival analysis.

Results: A total of 268 cases of PCLPD were recorded from 1973 to 2004. Median age at diagnosis was 61 years (range, 5 to 98 years). Among cases, 58% were male, and 42% female. Race distribution was 87% white, 7% black, and 4% Asian/Pacific Islander. A total of 157 patients had primary, localized PCLPD. For the total population (N = 268), overall survival at 3 years was 81% (95% CI, 74% to 87%). Population-matched relative survival at 3 years was 87% (SE, 3.6%). Disease-specific survival at 5 years was 92% (95% CI, 86% to 95%). Head and neck skin site predicted for inferior overall survival in patients with primary, localized PCLPD on univariable analysis (hazard ratio [HR] = 4.4; P = .008; 95% CI, 1.5 to 13.2), and was suggestive of decreased overall survival on multivariate analysis (HR = 3.0; P = .06; 95% CI, 0.95 to 9.7).

Conclusion: Localized PCLPDs are rare diseases with an excellent overall survival and occur more frequently in whites and in men. Head and neck skin primary site may be associated with poorer survival. Conclusions regarding subsets demonstrating association with survival should be taken with caution, given the small number of deaths analyzed.

Presented at the 49th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 28–November 1, 2007, Los Angeles, CA, and was published in abstract form by the International Journal for Radiation Oncology, Biology, and Physics.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.